Ameriprise’s Capricor Therapeutics CAPR Stock Holding History

Ameriprise’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-125,169	Closed	-$3.61M	–	4082
2025 Q4	$3.61M	Buy	+125,169	New	+$1.63M	﹤0.01%	2668

Other funds holding CAPR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JHC

Jones Hill Capital New York $466M AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ameriprise's CAPR Position: Q1 2026 in Review

Ameriprise sold out of Capricor Therapeutics (CAPR) in Q1 2026, closing a stake of 125,169 shares — an estimated $3.61M sold.

Ameriprise first reported a position in CAPR in Q4 2025 and held it in 1 quarter. The position peaked at $3.61M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

Ameriprise reported no remaining Capricor Therapeutics position as of Q1 2026 after selling out during the quarter.
Ameriprise sold 125,169 Capricor Therapeutics shares in Q1 2026, an estimated $3.61M.
Ameriprise first reported a position in Capricor Therapeutics in Q4 2025 and held it in 1 quarter.
Ameriprise's Capricor Therapeutics position peaked at $3.61M in Q4 2025.
177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.